Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
INNOventure is a venture capital fund established in Poland by Marcin Bielówka and Marcin Molo. The firm focuses on supporting innovative scientists, engineers, and entrepreneurs in developing and commercializing their projects. INNOventure is based in Krakow and operates under the BRIdge Alfa program, a joint initiative of Krakowski Park Technologiczny and SATUS Venture, coordinated by the National Centre for Research and Development (NCBiR). The fund has a total size of PLN 30 million (approximately €7 million), with 80% of its capital sourced from European funds and 20% from private investors.
The firm primarily targets early-stage companies, particularly those emerging from Polish universities and research institutes. INNOventure has a strong emphasis on sectors such as healthcare, IoT, AI, marketing, insurtech, and biotech. The fund's mission is to provide seed capital, mentorship, and support to help founders make their projects attractive to customers and future investors. Over the years, INNOventure has built a reputation for its commitment to fostering innovation and commercialization in the Polish tech landscape.
INNOventure invests in a variety of sectors, including healthcare, IoT, AI, marketing, insurtech, and biotech. The firm primarily focuses on pre-seed and seed stage investments, with check sizes ranging from €100,000 to €1.5 million per deal. The fund's investment strategy is centered around building value based on research and development outcomes, making it a first-contact investor for innovative founders. INNOventure seeks to support companies that have a strong R&D component and aims to help them commercialize their projects effectively.
The firm looks for founders who are scientists, engineers, or entrepreneurs with a clear vision for their projects. INNOventure emphasizes the importance of mentorship and connects founders with experienced professionals who can provide guidance throughout the development process. The fund's geographic focus is primarily on Poland, targeting spin-offs from local universities and research institutes. This approach allows INNOventure to bridge the gap between academic research and commercial viability, ensuring that innovative ideas can reach the market successfully.
INNOventure's portfolio includes several notable companies that exemplify its investment focus. Key portfolio companies are:
In addition to its current portfolio, INNOventure has been involved with companies that have successfully exited, including a global platform for translation services and a telemedicine device that enables remote care. The firm has also supported technologies in oncology diagnostics and monitoring, showcasing its commitment to impactful innovations in healthcare and technology.
Marcin Bielówka: Managing Partner at INNOventure, Marcin is recognized in the Polish VC ecosystem and has experience speaking at NCBR conferences. He has a strong background in supporting companies that have raised significant capital.
Marcin Molo: Co-manager of the fund, Marcin plays a key role in investment portfolio development and has a track record of working with early-stage companies.
Leszek Skowron: Project Development Support, Leszek assists portfolio companies in refining their projects and strategies.
Krzysztof Homziuk: Business Project Manager, Krzysztof focuses on operational aspects and helps ensure that projects align with market needs.
Karol Kaczmarczyk: Investment Acquisition and Portfolio Support, Karol is involved in sourcing new investment opportunities and supporting existing portfolio companies.
To pitch to INNOventure, founders should visit the firm's website at innoventure.vc. It is advisable to include a comprehensive pitch deck that outlines the business model, market opportunity, and team qualifications. INNOventure prefers to receive pitches through their website, and response times may vary based on the volume of submissions.
In recent months, INNOventure has been active in supporting the commercialization of research at Polish universities through its partnership with NCBR. The firm has participated in various conferences and events to promote its investment strategy and connect with potential founders.
As of March 2026, INNOventure continues to seek innovative projects in its target sectors, with a focus on early-stage investments that leverage research and development outcomes.
What are INNOventure's investment criteria?
INNOventure primarily invests in early-stage companies across sectors such as healthcare, IoT, AI, marketing, insurtech, and biotech. The fund focuses on projects with a strong research and development component, targeting pre-seed and seed stages.
How can I pitch to INNOventure?
Founders can pitch their ideas through INNOventure's website. It is recommended to include a detailed business plan and information about the team and technology in the pitch deck.
What makes INNOventure different from other VCs?
INNOventure operates as a first-contact investor, providing not only capital but also mentorship and support to help founders commercialize their projects. The firm has a strong focus on bridging the gap between academic research and commercial viability.
What is the typical check size for investments?
INNOventure typically invests between €100,000 and €1.5 million per deal, depending on the stage and needs of the startup.
What is the geographic focus of INNOventure?
The firm primarily focuses on investments in Poland, particularly in spin-offs from Polish universities and research institutes.
What kind of support can portfolio companies expect?
INNOventure provides operational support, mentorship, and connections to experienced professionals in the industry. The firm also assists in positioning companies for future fundraising rounds.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.